Press Releases

Progress Also Reported On Additional Nasdaq Compliance Issue   BETHESDA, MD, June 30, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced it had filed an 8-K today relating to two outstanding Nasdaq issues, including progress on a remediation plan relating to certain prior stock issuances. On June 24, 2016, Northwest... Read More

Leading Experts in Immunotherapies and Oncology From Both the US and Europe   BETHESDA, MD, June 13, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immunotherapies for solid tumor cancers, announced its Scientific Advisory Board (SAB) comprised of leading experts in immunotherapies and oncology from both the U.S. and Europe. The Company anticipates that the SAB... Read More

New Developments Relating to Phase I and II Trials, Scientific Advisory Board and Nasdaq Compliance   BETHESDA, MD, May 2, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today an operations update in regard to its Phase I and II Trials, Scientific Advisory Board and Nasdaq compliance. The Company has reached... Read More

BETHESDA, Md., February 29, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with current institutional investors for a registered direct offering with gross proceeds of up to approximately $27.6 million, assuming exercise in full of the overallotment option described... Read More

BETHESDA, Md., January 25, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is expanding its Board of Directors through the appointment of Ms. Susan Bayh and Ambassador Cofer Black as independent Directors.  Neither Ms. Bayh nor Ambassador Black has worked with the Company previously. Ms. Bayh brings to NW... Read More